| Literature DB >> 22949871 |
Limin Ning1, Xiaoxi Li1, Xiaorong Ding2,3, Yongmei Yin3, Genxi Li1,2.
Abstract
This paper reports a method for electrical communication between the inner part of cells and an electrode with the help of iRGD peptide. Due to the enhancement of the cell penetration caused by iRGD peptide, DNA molecules, previously modified on a gold electrode surface, can be easily transfected into the cells. At the same time, doxorubicin, an anticancer drug, can also be transfected into cells with high penetration. Consequently, doxorubicin binds to DNA chains through electrostatic interaction, and the redox reaction is transferred out of the cell across the cell membrane. As a result, this work may provide a novel way to get information from inside of cells.Entities:
Keywords: cell adhesion; cell penetration; doxorubicin; electrochemistry; iRGD
Mesh:
Substances:
Year: 2012 PMID: 22949871 PMCID: PMC3431869 DOI: 10.3390/ijms130810424
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Scheme 1Schematic illustration of the electrical communication between the inner part of cells and an electrode.
Figure 1Electrochemical impedance spectra (Nyquist plots) of the DNA modified electrode (I) before and (II) after its incubation with (a) 22Rv1 cells which were treated with both 100 μM iRGD and 50 μM doxorubicin, or (b) 50 μM doxorubicin. Curve (III) is the case of further treatment with cell lysis buffer; Test solution: 1 M KNO3 containing 5 mM Fe(CN)63−/4−. Biasing potential: 0.222 V. Amplitude: 5 mV. Frequency range: 0.1 Hz to 100 kHz.
Figure 2Cyclic voltammograms for a 50 mM Tris-HCl buffer (pH 7.4) obtained at the DNA-modified electrode after its incubation with 22Rv1 cells which were previously pretreated by (a) 50 μM doxorubicin and (I) 0 μM, (II) 20 μM, (III) 100 μM iRGD, or (b) 100 μM iRGD and (I) 0 μM, (II) 50 μM, (III) 100 μM doxorubicin. Scan rate: 100 mV s−1.
Figure 3(a) Cyclic voltammogram for a 50 mM Tris-HCl buffer (pH 7.4) obtained at the bare gold electrode after its incubation with 22Rv1 cells which were previously pretreated by 50 μM doxorubicin and 100 μM iRGD; (b) Cyclic voltammogram for a 50 mM Tris-HCl buffer (pH 7.4) obtained at the DNA-modified electrode after its incubation with 22Rv1 cells which were previously pretreated by 50 μM doxorubicin and 100 μM control peptide with its sequence LRRASLGGGGC; (c) Cyclic voltammogram for a 50 mM Tris-HCl buffer (pH 7.4) obtained at the DNA-modified electrode after its incubation with 293T cells which were previously pretreated by 50 μM doxorubicin and 100 μM iRGD.